ArticleCureus2025
Contrast-Enhanced Ultrasound-Guided Liver Tumor Biopsy for Primary Hepatic Angiosarcoma: A Case Series.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Management of Primary Hepatic Angiosarcoma: A Comprehensive Review.Journal of gastrointestinal cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary hepatic angiosarcoma (PHA) is a rare and aggressive malignant liver tumor that is often difficult to diagnose due to its nonspecific clinical presentation and imaging findings. This case series aimed to illustrate the utility of contrast-enhanced ultrasound (CEUS)-guided percutaneous liver biopsy for the definitive diagnosis of unresectable PHA. We report three patients who presented with nonspecific symptoms and hepatic masses. Imaging findings were inconclusive for a definitive diagnosis, and histopathological evaluation was required. All patients underwent CEUS-guided percutaneous liver tumor biopsy. CEUS enabled real-time visualization of viable tumor regions, facilitating accurate needle placement and minimizing sampling from necrotic or hemorrhagic areas. In Case one, multiple punctures were needed to obtain viable tissue due to extensive necrosis. In Cases two and three, CEUS was particularly useful for demarcating poorly defined lesions, resulting in successful tissue sampling with fewer punctures. Biopsies were performed during the post-vascular phase, enhancing diagnostic yield. Histopathological analysis revealed CD31-positive spindle-shaped cells and a high Ki-67 index, confirming the diagnosis of PHA in all cases. All patients died within six months of diagnosis despite chemotherapy, underscoring the poor prognosis and clinical urgency. CEUS-guided percutaneous liver biopsy is a minimally invasive and reliable technique for the diagnosis of PHA, especially in patients who are not candidates for surgery. This approach enables targeted tissue acquisition, potentially improves diagnostic accuracy, and may contribute to the earlier management of this rare malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.